Health X Platform delivered its strongest quarterly performance to date in Q1 FY27, driven by robust growth across its B2B and B2C segments. Revenue from operations rose 58% year-on-year to ₹440 crore, marking a sequential improvement of over 16% from ₹378 crore in Q4 FY26. The company returned to profitability, reporting a net profit of ₹2 crore, a significant turnaround from the net loss of ₹13 crore recorded in the preceding quarter.

Financial Performance

The top-line momentum was supported by an expansion in gross profit, which grew 64% year-on-year to ₹34 crore. Gross margin improved sequentially to 7.8% from 7.3% in Q4 FY26. Operating efficiency also showed signs of stabilization, with EBITDA loss narrowing to ₹15 crore from ₹20 crore in the prior quarter, translating to an EBITDA margin improvement to negative 3.4% from negative 5.5%. Despite these gains, management noted that higher employee and other operating expenses continued to impact EBITDA levels.

*Derived from disclosed growth rates and current figures.

Segment Growth and Strategy

Growth was broad-based across the company’s core platforms. The B2B segment, RetailerShakti, expanded 48% year-on-year, while the B2C platform, SastaSundar, grew 44% year-on-year. Management highlighted that 69.4% of RetailerShakti orders exceeded ₹2,500, indicating deeper wallet share among retailers. Similarly, 69.2% of SastaSundar orders were above ₹1,000, reflecting healthy consumer basket sizes.

Geographical expansion remains a key strategic pillar. While West Bengal continues to contribute approximately 30% of revenue, the company has accelerated penetration into Odisha, Bihar, Jharkhand, and Chhattisgarh. Northern operations have been strengthened through new infrastructure in Noida, with further expansion into Haryana, Uttar Pradesh, and Rajasthan. Management noted that tier-2 and tier-3 markets now account for 67% of RetailerShakti business and 78% of SastaSundar business.

What the Numbers Show

A critical observation from the quarter is the divergence between operational losses and net profitability. While EBITDA remained negative at ₹15 crore due to heavy investments in technology and expansion, the company reported a net profit of ₹2 crore. This discrepancy is largely attributable to significant other income, primarily treasury income from capital reserves built after the sale of the SastaSundar business to Flipkart. This structure suggests that current net profitability is not yet driven by core operations but rather by financial assets, highlighting that the underlying business model is still in an investment phase with high burn rates directed toward technology and geographic scaling.

Outlook and Investments

Management indicated that July 2026 revenue crossed ₹150 crore, suggesting sustained momentum into Q2. The company is focusing on launching RetailAir, an AI-monitored SaaS product for retailers, expected in the next quarter. Additionally, the private label initiative, JITO, saw revenue rise from ₹25 lakh in Q4 FY26 to ₹79 lakh in Q1 FY27, with gross margins exceeding 50%. Fulfillment infrastructure is being scaled with new warehouses in Noida, Guwahati, Lucknow, and Udaipur to support projected growth, with existing capacity sufficient to handle up to ₹3,000 crore in annual revenue.

Health X Platform Limited published its unaudited financial results for the quarter ended June 30, 2026, in Business Standard and Ek Din newspapers on August 8, 2026. This publication fulfills the company’s obligation under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure confirms the consolidated net profit of ₹198.67 lakh and total revenue from operations of ₹44,684.98 lakh previously reported, ensuring wider accessibility of financial data for investors and stakeholders.

The Board of Directors had approved these results on August 7, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by statutory auditors J K V S & Co. Chairman and Managing Director Banwari Lal Mittal signed off on the results, which are also available on the company’s website and stock exchange portals via a Quick Response (QR) code.

Financial Performance Highlights

The company’s consolidated revenue from operations grew 50% year-on-year to ₹44,684.98 lakh, up from ₹29,842.82 lakh in Q1FY25. Net profit after tax stood at ₹198.67 lakh, reversing a net loss of ₹1,296.88 lakh in the previous quarter. However, this represents a significant decline from the ₹2,659.21 lakh profit recorded in Q1FY25. Earnings per share (basic and diluted) were ₹0.80, compared to a loss per share of ₹3.51 in Q4FY26 and earnings of ₹7.52 in Q1FY25.

Standalone results showed a net loss of ₹51.43 lakh for the quarter, compared to a loss of ₹15.20 lakh in the previous quarter and ₹10.95 lakh in Q1FY25. Standalone revenue from operations remained flat at ₹8.00 lakh.

Segment-wise Analysis

The Healthcare Network segment remained the primary revenue driver, contributing ₹41,177.80 lakh to total revenue, a substantial increase from ₹27,853.90 lakh in Q1FY25. However, this segment reported a segment result loss of ₹1,486.95 lakh, narrowing from the ₹2,314.40 lakh loss in the prior quarter. The Financial Services segment generated ₹655.75 lakh in revenue and posted a segment profit of ₹557.18 lakh, up from a loss of ₹500.68 lakh in Q4FY26.

What the Numbers Show

The sequential reversal to profitability in Q1FY26 was significantly aided by non-operating factors. While the Healthcare Network's operational losses narrowed, the overall profit figure includes a tax credit of ₹48.94 lakh against current tax expenses of ₹47.75 lakh. Furthermore, the 'Others' segment contributed ₹2,851.43 lakh in revenue with a profit of ₹54.82 lakh, indicating diversification efforts are yielding returns. However, investors should note that the standalone entity continues to incur losses, highlighting that the group-level profitability is currently sustained by its subsidiaries' performance rather than the holding company's core operations.

Corporate Developments and Disclosures

The Board had previously approved a Composite Scheme of Arrangement and Amalgamation involving Health X Platform Limited, Microsec Resources Private Limited, Innogrow Technologies Limited, and Sastasundar Healthbuddy Limited, with an appointed date of April 01, 2026. No accounting effect has been given in the Q1FY26 results pending requisite approvals. The company incurred ₹14.75 lakh in expenses related to this scheme during the quarter.

Statutory auditors J K V S & Co highlighted a material uncertainty regarding the going concern status of step-down subsidiary Genu Path Labs Limited (GPLL). GPLL's net worth has completely eroded, and its current liabilities exceed current assets. Despite this, GPLL's financials have been prepared on a going concern basis, supported by assurances of continued financial support from Sastasundar Healthbuddy Limited.